| SE8205892D0              (en) | 1982-10-18 | 1982-10-18 | Bror Morein | IMMUNOGENT MEMBRANE PROTEIN COMPLEX, SET FOR PREPARATION AND USE THEREOF | 
| JP2851288B2              (en) | 1987-06-05 | 1999-01-27 | アメリカ合衆国 | Autocrine motility factors in cancer diagnosis and management | 
| US4912094B1              (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation | 
| GB8819209D0              (en) | 1988-08-12 | 1988-09-14 | Research Corp Ltd | Polypeptide & dna encoding same | 
| EP0449856B1              (en) | 1988-12-16 | 2001-09-12 | De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur | Pneumolysin mutants and pneumococcal vaccines made therefrom | 
| EP0614465B1              (en) | 1991-11-16 | 1999-03-17 | SMITHKLINE BEECHAM BIOLOGICALS s.a. | HYBRID PROTEIN BETWEEN CS FROM PLASMODIUM AND HBsAG | 
| SG90042A1              (en) | 1992-06-25 | 2002-07-23 | Smithkline Beecham Biolog | Vaccine composition containing adjuvants | 
| BR9405957A              (en) | 1993-03-23 | 1995-12-12 | Smithkline Beecham Biolog | Vaccine compositions containing 3-0 monophosphoryl deacylated lipid A | 
| GB9326253D0              (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines | 
| UA56132C2              (en) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Vaccine composition (variants), method for stabilizing qs21 providing resistance against hydrolysis (variants), method for manufacturing vaccine | 
| US5843464A              (en) | 1995-06-02 | 1998-12-01 | The Ohio State University | Synthetic chimeric fimbrin peptides | 
| GB9711990D0              (en) | 1997-06-11 | 1997-08-06 | Smithkline Beecham Biolog | Vaccine | 
| HUP0002475A3              (en) | 1997-07-21 | 2002-01-28 | Baxter Healthcare S A Wallisel | Modified immunogenic pneumolysin compositions as vaccines | 
| DE69929310T2              (en) | 1998-02-05 | 2006-08-03 | Glaxosmithkline Biologicals S.A. | TUMOR ASSOCIATED ANTIGEN DERIVATIVES OF THE MAGE FAMILY, NUCLEIC ACID SEQUENCES THAT CODE FOR THE PREPARATION OF FUSION PROTEINS AND COMPOSITIONS FOR VACCINATION | 
| WO1999051748A2              (en) | 1998-04-07 | 1999-10-14 | Corixa Corporation | Fusion proteins of mycobacterium tuberculosis antigens and their uses | 
| ATE362994T1              (en)* | 1998-06-30 | 2007-06-15 | Sloan Kettering Inst Cancer | USE OF DNA PK | 
| DE60014076T2              (en) | 1999-04-19 | 2005-10-13 | Glaxosmithkline Biologicals S.A. | ADJUVANS COMPOSITION, CONTAINING SAPONINE AND AN IMMUNOSTIMULATORY OLIGONUCLEOTIDE | 
| US6558670B1              (en) | 1999-04-19 | 2003-05-06 | Smithkline Beechman Biologicals S.A. | Vaccine adjuvants | 
| GB0019375D0              (en) | 2000-08-07 | 2000-09-27 | Int Centre Genetic Eng & Bio | Method of polypeptide renaturation | 
| CA2461056A1              (en) | 2001-09-20 | 2003-03-27 | Glaxo Group Limited | Hiv-gag codon-optimised dna vaccines | 
| JP4787936B2              (en) | 2004-05-26 | 2011-10-05 | サイオクサス  セラピューティクス  リミティド | Chimeric adenovirus for use in cancer treatment | 
| GB0417494D0              (en) | 2004-08-05 | 2004-09-08 | Glaxosmithkline Biolog Sa | Vaccine | 
| EP1851314A2              (en) | 2005-02-24 | 2007-11-07 | Coley Pharmaceutical Group, Inc. | Immunostimulatory oligonucleotides | 
| WO2006104890A2              (en) | 2005-03-31 | 2006-10-05 | Glaxosmithkline Biologicals Sa | Vaccines against chlamydial infection | 
| ES2381492T3              (en) | 2005-04-29 | 2012-05-28 | Glaxosmithkline Biologicals Sa | Procedure for prevention or treatment of infection with M. tuberculosis | 
| CN101951947A              (en) | 2007-12-24 | 2011-01-19 | 葛兰素史密丝克莱恩生物有限公司 | Vaccines for malaria |